Don’t get me wrong - I’ll be delighted too, and I expect BOT to be a big payday, eventually. But as we saw with the SB acquisition, promising results and intentions just aren’t enough in the current market to drive decent price swings. Subsequently, I don’t expect much when rosa and derm results are announced, but would love to be terribly mistaken!
Ann: BOT Submits FDA New Drug Application for Sofpironium Bromide, page-55
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.8¢ |
Change
0.003(0.70%) |
Mkt cap ! $645.1M | |||
| Open | High | Low | Value | Volume |
| 35.5¢ | 36.0¢ | 35.5¢ | $72.86K | 203.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 683618 | 35.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.0¢ | 196220 | 9 |
View Market Depth
| Last trade - 10.07am 17/10/2024 (20 minute delay) ? |
| BOT (ASX) Chart |